^
Association details:
| Biomarker: | mTOR expression + RPS6KB1 expression |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus
Published date:
05/10/2020
Excerpt:
Twenty-four patients with advanced NETs that were treated with Eve were included in the analysis. Eight out 24 (33.3%) patients were both p-mTOR and p-S6K positive. A better median PFS and OS in group 1 (18.2 and 39.9 months) as compared to group 2 (13 and 32.4 months) was depicted...
DOI:
10.3390/cancers12051201
